Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fresenius Medical Care AGFMS +0.61%76 EV-to-EBITDA is 6.28 as of Jul. 25, 2026, which is 22% below its 10-year median of 8.10. GuruFocus rates FMS with a GF Score™ of 76/100 and a GF Value™ of $24.05 (Fairly Valued). The stock has 4 warning signs investors should review. Among 507 Healthcare Providers & Services companies, Fresenius Medical Care AG ranks better than 76.53% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Fresenius Medical Care AG's enterprise value is $25,004 Mil.
Fresenius Medical Care AG's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $3,981 Mil. Therefore, Fresenius Medical Care AG's EV-to-EBITDA for today is 6.28.
The historical rank and industry rank for Fresenius Medical Care AG's EV-to-EBITDA or its related term are showing as below:
FMS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.02 Med: 8.1 Max: 11.45
Current: 6.43
During the past 13 years, the highest EV-to-EBITDA of Fresenius Medical Care AG was 11.45. The lowest was 6.02. And the median was 8.10.
FMS's EV-to-EBITDA is ranked better than 76.53% of 507
companies
in the Healthcare Providers & Services industry
Industry Median: 10.92
vs FMS: 6.43
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Fresenius Medical Care AG (NYSE:FMS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Fresenius Medical Care AG's PE Ratio (TTM) for today is calculated as:
Fresenius Medical Care AG's share price for today is $24.59.
Fresenius Medical Care AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.912.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Fresenius Medical Care AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fresenius Medical Care AG EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fresenius Medical Care AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Fresenius Medical Care AG's EV-to-EBITDA falls into.
Fresenius Medical Care AG's current Enterprise Value is $25,004 Mil.
Fresenius Medical Care AG's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,981 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fresenius Medical Care AG (FMS) has a EV-to-EBITDA of 6.28 as of Jul. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Fresenius Medical Care AG. This is 22% below median its historical median of 8.10. Over the past decade, Fresenius Medical Care AG's EV-to-EBITDA has ranged from 6.02 to 11.45. According to the industry distribution chart, Fresenius Medical Care AG ranks #119 out of 507 companies in the Healthcare Providers & Services industry, placing it in the top 23.5%.
Is Fresenius Medical Care AG's EV-to-EBITDA too high?
Fresenius Medical Care AG's current EV-to-EBITDA of 6.28 is 22% below median its 10-year median of 8.10. Over the past 10 years, this metric has ranged from a low of 6.02 to a high of 11.45. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.92. Fresenius Medical Care AG's value of 6.28 is 42.5% below this industry median. Based on the distribution chart, Fresenius Medical Care AG ranks #119 out of 507 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Fresenius Medical Care AG has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fresenius Medical Care AG's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Fresenius Medical Care AG ranks #119 out of 507 companies for EV-to-EBITDA. This places Fresenius Medical Care AG in the top 24% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 10.92. Fresenius Medical Care AG's value of 6.28 is 42.5% below this benchmark. Historically, Fresenius Medical Care AG's own EV-to-EBITDA has ranged from 6.02 to 11.45 over the past decade. While the company's 10-year median is 8.10 vs. the industry median of 10.92, Fresenius Medical Care AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.92, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fresenius Medical Care AG's current EV-to-EBITDA of 6.28 is 42.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Fresenius Medical Care AG. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fresenius Medical Care AG's current EV-to-EBITDA is 6.28, which is 22% below median its own 10-year median of 8.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius Medical Care AG stock overvalued right now?
Based on GuruFocus' analysis, Fresenius Medical Care AG (FMS) is currently considered Fairly Valued. The stock's GF Value™ is $24.05, compared to a current price of $24.59 — trading 2.2% above its estimated fair value. The current EV-to-EBITDA is 6.28, which is 22% below median its 10-year median of 8.10 and 42.5% below the Healthcare Providers & Services industry median of 10.92. Fresenius Medical Care AG's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Fresenius Medical Care AG (FMS), the current EV-to-EBITDA is 6.28 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fresenius Medical Care AG (FMS) Overvalued in 2026?
Based on GuruFocus' analysis, Fresenius Medical Care AG stock appears to be overvalued.
The current stock price of $24.59 is trading 2.2% above its estimated GF Value™ of $24.05.
GuruFocus considers Fresenius Medical Care AG to be Fairly Valued.
Key valuation signals for FMS:
EV-to-EBITDA: 6.28 (22% below median its 10-year median of 8.10)
GF Value™: $24.05 vs. price of $24.59 (2.2% above fair value)
Industry Position: 42.5% below the Healthcare Providers & Services median (#119 of 507)
No single metric tells the full story. See the FMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
76GF Score
Get the complete analysis for FMS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FMS has been successfully added to your 
